<hoowh class="dmkssz"></hoowh>

人生就是搏

Be the most trusted biotech company

2024-07-02

Henlius Receives Approval in Japan for Phase 3 MRCT of Anti-PD-1 mAb Serplulimab Combo on First-Line mCRC
2024-06-28

Henlius Announces Successful Completion of Phase 1 Clinical Study of Daratumumab HLX15
2024-06-26

Henlius Shines at World ADC Asia 2024, Showcasing Its Innovative R&D Accomplishments in ADC Area
2024-06-21

IMF Chief Economist Visits Henlius: Witnessing China's Economic Vitality and Biopharmaceutical Innovation
2024-06-19

Results from the Preclinical Study of HLX99, an Innovative Neurodegenerative Diseases Therapeutic of Henlius Released at ENCALS Meeting 2024
2024-06-18

Henlius to Make Its Debut at the World ADC Asia 2024
2024-06-17

Advances in Immunotherapy for mCRC: Serplulimab Combo Published in MED
2024-06-12

Henlius Shines at 2024 BIO International Convention, Showcasing Its Innovative Strength and Global Achievements
2024-06-07

Henlius Expands Collaboration with Sermonix for Lasofoxifene in All of Asia